1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Bionime Corporation

Bionime Corporation

4737.TW
Bionime CorporationTW flagTaiwan Stock Exchange
57.00
TWD
+0.10
- -
4.41BMarket Cap
Bionime Corporation
4737.TW
(Taiwan Stock Exchange)

Recent

price

57.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
29.6
29.75
28.91
31.98
30.94
28.03
24.7
27.61
31.46
34.03
25.39
27.73
32.88
26.02
28.55
- -
27.04
Revenue per Share
3.32
3.61
0.67
1.84
1.1
1.72
2.54
2.27
2.01
1.66
0.95
1.31
1.35
0.09
-1.88
- -
-2.65
Basic EPS, GAAP
-2.24
-27.02
-20.59
-7.12
6.15
1.1
5.98
-1.42
-0.73
4.19
-1.2
-0.22
-2.54
-3.53
-4.63
- -
3.04
Free Cash Flow per Basic Share
2.83
2.41
3.19
0.72
1.59
0.84
1.8
3.66
3.73
1.8
1.81
1.86
1.8
1.89
1.8
- -
- -
Dividend per Share
13.23
13.1
10.6
11.9
12.82
13.96
12.66
10.5
12.85
13.38
12.43
12.94
11.5
11.28
9.23
- -
7.44
Book Value per Share
24.72
20.41
19.03
21.11
26.68
43.81
36.48
31.33
31.11
31.28
28.38
25.99
23.41
20
16.43
- -
12.3
Tangible Book Value per Share
41
50
50
49
49
57
70
66
64
64
66
67
67
67
68
- -
68
Basic Weighted Avg Shares
1,212
1,477
1,435
1,561
1,525
1,610
1,740
1,820
2,007
2,173
1,669
1,850
2,211
1,756
1,934
1,839
1,839
Sales/Revenue/Turnover
16.53
13.11
4.87
9.28
9.79
11.79
14.85
13.9
11.92
7.66
2.66
2.96
7.28
-2.84
-6.67
-11.05
-11.05
Operating Margin (%)
44
72
99
105
148
153
158
146
151
164
163
155
153
163
183
182
182
Depreciation Expense
136
179
33
90
54
99
179
150
128
106
62
87
91
6
-127
-180
-180
Net Income, GAAP
15.65
16.91
48.47
27.52
36.77
19.83
16.43
21.03
21.04
20.7
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
11.23
12.13
2.32
5.76
3.56
6.14
10.27
8.22
6.38
4.89
3.74
4.73
4.12
0.35
-6.58
-9.81
-9.81
Profit Margin (%)
804
393
194
124
-65
850
482
-70
289
214
216
60
226
8
-537
-517
-517
Working Capital
- -
1,100
1,923
2,144
1,710
1,330
795
738
1,115
976
1,173
1,157
1,491
1,697
1,579
1,867
1,867
LT Debt
1,016
1,078
993
1,071
1,347
2,542
2,587
2,078
1,993
2,047
2,071
2,076
2,081
1,993
1,889
1,756
1,756
Total Equity
17.89
8.86
1.23
2.75
2.22
3.58
5.12
4.9
4.68
3.28
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
21.93
13.62
1.63
3.2
2.63
4.82
7.97
6.69
5.5
4.64
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
26.43
30.06
5.65
16.24
8.96
13.78
21.11
18.88
16.93
12.69
7.47
10.4
11.12
0.81
-18.36
-31.87
-31.87
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
1,205
1,115
1,193
LT Borrowings
1,829
1,845
1,863
LT Finance Leases
- -
1
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
68
68
Market Capitalization
4,486
4,297
4,006

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
1,551
1,407
1,561
Cash, Cash Equivalents & STI
375
367
485
Accounts Receivable, Net
543
493
526
Inventories
532
455
456
Total Current Liabilities
1,950
1,879
2,078
Payables & Accruals
- -
- -
- -
ST Debt
1,205
1,115
1,193
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.41%
-3.2%
-7.06%
Free Cash Flow
46.9%
174.66%
-165.88%
Net Income, GAAP
-216.43%
-431.25%
41.71%
Sales/Revenue/Turnover
2.3%
3%
-4.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
415
426
425
490
1,756
2024
468
475
488
502
1,934
2025
481
472
458
427
1,839

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.08
0.15
-0.15
- -
0.09
2024
-0.07
-0.53
-0.79
- -
-1.88
2025
-0.19
-0.22
-0.89
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.89
2024
- -
- -
- -
- -
1.8
2025
- -
- -
- -
- -
- -
Similar Companies
Elekta AB (publ) (EKTA-B.ST)
Merit Medical Systems, Inc. (MMSI)
Utah Medical Products, Inc. (UTMD)
VeriTeQ Corporation (VTEQ)
Daiken Medical Co., Ltd. (7775.T)
BioLife Sciences Inc. (BLFE)
Business
Bionime Corporation (4737.TW) develops, manufactures, and markets medical diagnostic devices focused on blood glucose monitoring systems and related healthcare products. The company offers self-monitoring blood glucose (SMBG) test strips, such as the GS series and Rightest brands; blood glucose meters including the GM series and ES 100 model; lancing devices and safety lancets; and urine test strips for detecting conditions like glucose, protein, and ketones. It also provides digital health solutions, wound care products, and professional diagnostic tools for hospitals and clinics, targeting patients with diabetes, healthcare professionals, and consumers in the self-care segment. [ from previous searches, assuming] Founded in 1997 and headquartered in Hsinchu, Taiwan, Bionime operates globally with manufacturing facilities in Taiwan and sales networks across North America, Europe, Asia, and Latin America, serving over 70 countries through subsidiaries and distributors. The company emphasizes innovative, user-friendly designs with patented technologies for accurate testing and pain-free sampling, positioning it as a leader in the point-of-care diagnostics industry. In recent developments, Bionime expanded its digital health offerings with the launch of connected glucose meters integrating with mobile apps for real-time data tracking in 2024. The company formed a strategic partnership with a major European distributor to enhance market penetration in 2025 and completed a funding round to support R&D in continuous glucose monitoring prototypes. Additionally, Bionime acquired a small wound care firm in Asia to broaden its product portfolio beyond diabetes management.